helbred kraft uden medicin
-
ehm ding dong dynamo. hvordan synes i selv det går`?
Overview
The DuoBody
platform is a versatile platform technology for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies' specificity and efficacy in inactivating the disease target cells. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies, which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process that is easily performed at discovery scale as well as commercial manufacturing scale.The DuoBody
platform serves as the basis of many bispecific antibodies in Genmab's product pipeline as well as products of our partners and in 2021, the U.S. FDA approved the first therapy created using DuoBody technology platform. The DuoBody platform can be combined with Genmab's HexaBody platform (also known as Genmab's technology platform DuoHexaBody) as well as with other antibody engineering technologies.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind